Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Mar;68(3):423-433.
doi: 10.1136/gutjnl-2017-315568. Epub 2018 Jan 23.

Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study

Johan Burisch  1 , Gediminas Kiudelis  2 , Limas Kupcinskas  2   3 , Hendrika Adriana Linda Kievit  4 , Karina Winther Andersen  5 , Vibeke Andersen  5   6 , Riina Salupere  7 , Natalia Pedersen  8 , Jens Kjeldsen  9 , Renata D'Incà  10 , Daniela Valpiani  11 , Doron Schwartz  12 , Selwyn Odes  12 , Jóngerð Olsen  13 , Kári Rubek Nielsen  13 , Zsuzsanna Vegh  14 , Peter Laszlo Lakatos  14   15 , Alina Toca  16 , Svetlana Turcan  16 , Konstantinos H Katsanos  17 , Dimitrios K Christodoulou  17 , Mathurin Fumery  18 , Corinne Gower-Rousseau  19   20 , Stefania Chetcuti Zammit  21 , Pierre Ellul  21 , Carl Eriksson  22 , Jonas Halfvarson  22 , Fernando Jose Magro  23   24 , Dana Duricova  25 , Martin Bortlik  25   26 , Alberto Fernandez  27 , Vicent Hernández  28 , Sally Myers  29 , Shaji Sebastian  29 , Pia Oksanen  30   31 , Pekka Collin  31 , Adrian Goldis  32 , Ravi Misra  33 , Naila Arebi  33 , Ioannis P Kaimakliotis  34 , Inna Nikuina  35 , Elena Belousova  35 , Marko Brinar  36 , Silvija Cukovic-Cavka  36 , Ebbe Langholz  37 , Pia Munkholm  1 ; Epi-IBD group
Collaborators, Affiliations
Multicenter Study

Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study

Johan Burisch et al. Gut. 2019 Mar.

Abstract

Objective: The Epi-IBD cohort is a prospective population-based inception cohort of unselected patients with inflammatory bowel disease from 29 European centres covering a background population of almost 10 million people. The aim of this study was to assess the 5-year outcome and disease course of patients with Crohn's disease (CD).

Design: Patients were followed up prospectively from the time of diagnosis, including collection of their clinical data, demographics, disease activity, medical therapy, surgery, cancers and deaths. Associations between outcomes and multiple covariates were analysed by Cox regression analysis.

Results: In total, 488 patients were included in the study. During follow-up, 107 (22%) patients received surgery, while 176 (36%) patients were hospitalised because of CD. A total of 49 (14%) patients diagnosed with non-stricturing, non-penetrating disease progressed to either stricturing and/or penetrating disease. These rates did not differ between patients from Western and Eastern Europe. However, significant geographic differences were noted regarding treatment: more patients in Western Europe received biological therapy (33%) and immunomodulators (66%) than did those in Eastern Europe (14% and 54%, respectively, P<0.01), while more Eastern European patients received 5-aminosalicylates (90% vs 56%, P<0.05). Treatment with immunomodulators reduced the risk of surgery (HR: 0.4, 95% CI 0.2 to 0.6) and hospitalisation (HR: 0.3, 95% CI 0.2 to 0.5).

Conclusion: Despite patients being treated early and frequently with immunomodulators and biological therapy in Western Europe, 5-year outcomes including surgery and phenotype progression in this cohort were comparable across Western and Eastern Europe. Differences in treatment strategies between Western and Eastern European centres did not affect the disease course. Treatment with immunomodulators reduced the risk of surgery and hospitalisation.

Keywords: crohn’s disease; epidemiology; surgery for Ibd.

PubMed Disclaimer

Conflict of interest statement

Competing interests: JB: consulting fees from Celgene, Janssen-Cilag, AbbVie A/S and Ferring and lecture fees from Abbvie A/S, Pfizer, MSD and Takeda Pharma A/S. VA: consultancy for Janssen and MSD. RS: consulting fees and/or lecture fees from AbbVie, MSD, Takeda, Janssen-Cilag. RD’I: consulting fees from Abbvie, Biocure and lecture fees from Takeda and Mundipharma. MF: speaker/lecture fees for Abbvie, Ferring, MSD, Takeda, Boehringer and Hospira. CG-R: lecture fees from Takeda, MSD, Ferring and Tillots. CE: lecture fees from Takeda. JH: research grants from Janssen, MSD and Takeda and lecture and/or consultancy fees from Abbvie, Cellgene, Ferring, Hospira, Janssen, Medivir, MSD, Pfizer, Vifor Pharma, Takeda and Tillotts Pharma. EL: lecture or consultancy fees from MSD, Abbvie and Ferring Pharmaceuticals. DD: lecture or consultancy fees from AbbVie, Takeda and Janssen. NA: lecture fees from MSD and Jansen. VH: personal fees, non-financial support and other from MSD, AbbVie, Ferring, Faes Farma, Shire, Falk Pharma, Tillots, Otsuka, Hospira Biologicals, Takeda, Jansen and Kernpharma Biologics. AF: personal fees and non-financial support from MSD, AbbVie, Shire and Tillots. SČ-Č: lecture fees from Takeda, MSD, Abbvie.

Publication types

MeSH terms

LinkOut - more resources